Saturday, 17 October 2026European Markets

ONWARD MEDICAL Stock 10% Up On Tuesday

Loading stream...

(VIANEWS) - The Market ended the session with ONWARD MEDICAL (ONWD.BR) jumping 10% to €3.74 on Tuesday, after five successive sessions in a row of gains. BEL 20 dropped 0.32% to €3,462.94, following the last session's downward trend on what was a somewhat negative trend exchanging session today.

ONWARD MEDICAL's last close was €3.40, 48.95% below its 52-week high of €6.66.

About ONWARD MEDICAL

Onward Medical N.V., a medical technology company, focuses on developing therapies for spinal cord injuries in the Netherlands and internationally. The company engages in developing ARC-EX, an external non-invasive platform that consists of a wearable stimulator and wireless programmer; and ARCIM, an implantable platform, which consists of an implantable pulse generator and lead that is placed near the spinal cord. It also engages in developing Up-LIFT Trial to evaluate the safety and effectiveness of non-invasive electrical spinal cord stimulation to treat upper extremity functional deficits with chronic tetraplegia. The company was founded in 2014 and is headquartered in Eindhoven, Netherlands.

Earnings Per Share

As for profitability, ONWARD MEDICAL has a trailing twelve months EPS of €-1.2.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -69.93%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ONWARD MEDICAL's stock is considered to be oversold (<=20).

Yearly Top and Bottom Value

ONWARD MEDICAL's stock is valued at €3.74 at 21:31 EST, way below its 52-week high of €6.66 and way higher than its 52-week low of €2.93.

Revenue Growth

Year-on-year quarterly revenue growth declined by 3.6%, now sitting on 2.11M for the twelve trailing months.

Moving Average

ONWARD MEDICAL's value is above its 50-day moving average of €3.70 and way under its 200-day moving average of €4.77.

More news about ONWARD MEDICAL (ONWD.BR).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Autumn 2026 Governance Reshuffle: CEO Successions, Activist Settlements and Corporate Separations
Across sectors, boards are replacing or rotating leadership (Bausch + Lomb's abrupt CEO exit, Keyser's move to advisor, Deputy CEO promotions, Brown-Forman and BellRing successions). At the same time, activist pressure is being settled through cooperation agreements and board seats (Stride/Fivespan, Al Shams) and through structural separations (National Fuel's IUG spin-out, NGEx). The common thread is boards using governance levers such as new committees, advisory seats and planned succession to reset capital allocation and strategy. Public messaging stresses continuity and partnership, but the number of interim appointments and activist-driven changes points to underlying pressure.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,384 source documents archived
Query this data → isubstrate.com